Search Results

Now showing 1 - 6 of 6

Some of the metrics are blocked by your
consent settings
Rituximab in treatment of a patient with granulomatosis with polyangitis - a case report
(Македонско лекарско друштво = Macedonian medical association, 2023-01)
;
Guchev, Filip
;
Antova, Dubravka
;
Karadzova Stojanovska, Anzhelika
;
Vidinikj, Sonja
ANCA-associated vasculitis (AAV) is a necrotizing vasculitis with few or no immune deposits that can affect predominantly small vessels. It can affect vessels in every organ and tissue of the body; the clinical manifestations of the disease are extremely variable. B-cells are of major importance in the disease pathogenesis as precursors of ANCA-producing plasma cells and, possibly, also as antigen-presenting and cytokineproducing cells. Therefore, rituximab, a monoclonal antibody drug causing partial B-cell depletion, has emerged as a powerful option in the treatment of AAV such as granulomatosis with polyangiitis. We present the case of a 25-year-old female diagnosed with granulomatosis with polyangiitis and treated with rituximab and high-dose corticosteroids.
Some of the metrics are blocked by your
consent settings
Severe Complicated secondary antiphospholipid syndrome conjointly with lupus erythematosus -case report
(Macedonian Academy of Sciences and Arts/Walter de Gruyter GmbH, 2025-01)
Vidinikj, Sonja
;
Antova, Dubravka
;
;
Guchev, Filip
;
Antiphospholipid syndrome (APS), is an autoimmune systemic disorder known to manifest with thrombosis in almost all vessels throughout the body, can also be accompanied by pregnancy morbidity, and is persistent with the presence of antiphospholipid antibodies, including lupus anticoagulant antibodies, or relatively high titers of anticardiolipin, or anti-β2Glycoprotein I antibodies. APS can occur alone or in association with other diseases, more commonly systemic lupus erythematous. In patients with both underlying diseases episodes of arthritis, skin changes in the form of livedo reticularis, thrombocytopenia and leucopenia were more common. Cardiac manifestations have also been reported. Here we present a complicated case of a young female patient with antiphospholipid syndrome and an underlying systemic lupus erythematosus.
Some of the metrics are blocked by your
consent settings
A complicated case of granulomatosis with polyangiitis
(Macedonian Academy of Sciences and Arts/Walter de Gruyter GmbH, 2025-01)
Guchev, Filip
;
;
Vidinikj, Sonja
;
;
Granulomatosis with polyangiitis, formerly known as Wegener's granulomatosis, is a condition often presenting with granulomatous vasculitis of both the upper and lower respiratory tracts together with glomerulonephritis. Here we present a case of a 17-year-old female patient, who presented with symptoms of pansinusitis with other symptoms gradually following. She was treated with cyclophosphamide which was later switched to rituximab and is now in remission.
Some of the metrics are blocked by your
consent settings
RITUXIMAB IN TREATMENT OF A PATIENT WITH GRANULOMATOSIS WITH POLYANGIITIS – A CASE REPORT
(Македонско лекарско друштво = Macedonian medical association/De Gruyter, 2024-12-15)
Bojadzioska, Maja
;
Guchev, Filip
;
Antova, Dubravka
;
Karadzova-Stojanoska, Anzhelika
;
Vidinikj, Sonja
ANCA-associated vasculitis (AAV) is a necrotizing vasculitis with few or no immune deposits that can affect predominantly small vessels. It can affect ve-ssels in every organ and tissue of the body; the clinical manifestations of the disease are extremely variable. B-cells are of major importance in the disease patho¬ge¬nesis as precursors of ANCA-producing plasma cells and, possibly, also as antigen-presenting and cytokine-producing cells. Therefore, rituximab, a monoclonal anti¬body drug causing partial B-cell depletion, has emerged as a powerful option in the treatment of AAV such as granulomatosis with polyangiitis. We present the case of a 25-year-old female diagnosed with granu-lomatosis with polyangiitis and treated with rituximab and high-dose corticosteroids.
Some of the metrics are blocked by your
consent settings
Epidemiological Analysis and Geographical Distribution of Patients Suffering from Rheumatoid Arthritis, Eligible for First-Line Therapy/Monotherapy Treatment with Subcutaneous Formulation of Tocilizumab in the Republic of Macedonia
(Macedonian Academy of Sciences and Arts/Walter de Gruyter GmbH, 2018-12-01)
Gucev, Filip
;
Perchinkova-Mishevska, Snezana
;
Bozinovski, Georgi
;
;
Antova, Dubravka
Rheumatoid arthritis is an inflammatory arthritis characterized by synovial tissue inflammation that leads to structural damage and disability. There are several treatment options available, which include glucocorticoids, DMARDs and biologics given alone as monotherapy or in a variety of combinations. Recent evidence has shown that early treatment is important in reducing the rate of progression of erosions and decreasing disability. The lack of adequate statistical data on number of patients that are eligible for first-line therapy/monotherapy of rheumatoid arthritis in Macedonia, triggered this epidemiological analyse describing eligible patients for first-line treatment/monotherapy distributed by gender, age and geographical allocation. The study was conducted by fulfilling a tailored questionnaire every two months in a period of six months (September 2017-February 2018) by including summarized data not related to personal data of patients nor specific drug information. The results have shown that a total of 115 patients in Macedonia are eligible for first-line therapy, whereby 54 (46%) patients were eligible for monotherapy of rheumatoid arthritis. Precise determination of these data provides patients' determination by geographical allocation and proper selection of the best treatment option and optimized therapy for each patient, furthermore when subcutaneous formulation of tocilizumab is available as an effective clinically proven treatment option for RA.
Some of the metrics are blocked by your
consent settings
Multicenter, Open-Label, Long-term Extension to Describe the Safety of Tocilizumab in Patients with Early, Moderate to Severe Rheumatoid Arthritis
(Science Publishing Group, 2020)
;
;
Antova, Dubravka
;
Kotevska Nikolova, Mimoza
;
Stojanovska, Anzhelika

Faculty of Medicine

Browse

Filters

Settings

Sort By

Results per page

Search Results